Латентный аутоиммунный диабет у взрослых: современные представления о факторах риска, диагностике и терапии

1. Irvine W.J., McCallum C.J., Gray R.S., Duncan L.J. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet. 1977;1(8020):1025–7. Doi: 10.1016/s0140-6736(77)91258-2.

2. Buzzetti R., Tuomi T., Mauricio D., et al. Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes. 2020;69(10):2037–47. Doi: 10.2337/dbi20-0017.

3. Antar S.A., Ashour N.A., Sharaky M., et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023; 168:115734. Doi: 10.1016/j.biopha.2023.115734.

4. Gatta E., Anelli V., Cimino E., et al. Autoimmune polyglandular syndrome type 4: experience from a single reference center. Front Endocrinol (Lausanne). 2023; 14:1236878. Doi: 10.3389/fendo.2023.1236878.

5. Frommer L., Kahaly G.J. Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link. Front Endocrinol (Lausanne). 2021; 12:618213. Doi: 10.3389/fendo.2021.618213.

6. Goodwin G. Type 1 Diabetes Mellitus and Celiac Disease: Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms. Horm Res Paediatr. 2019;92(5):285–92. Doi: 10.1159/000503142.

7. Ahlqvist E., Storm P., Käräjämäki A., et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet. Diab Endocrinol. 2018. 6(5): 361–369. DOI: 10.1016/ S2213-8587(18)30051-2.

8. Мамедов М.Н., Канорский С.Г., Мкртумян А.М. и др. Обновленные европейские рекомендации по лечению сердечно-сосудистых заболеваний при сахарном диабете 2023: мнение российских экспертов. Международный журнал сердца и сосудистых заболеваний. 2023;11(40 Suppl. 1):3–51.

9. Мамедов М.Н., Канорский С.Г., Арабидзе Г.Г. и др. Сердечно-сосудистые заболевания и управление рисками: стандарты при сахарном диабете 2023 (рекомендации АДА). Мнение российских экспертов. Международный журнал сердца и сосудистых заболеваний. 2023;11(40):5–27.

10. Stone S.I., Balasubramanyam A., Posey J.E. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diab Care. 2024;47(5):770–81. Doi: 10.2337/dci23-0038.

11. Кононенко И.В., Смирнова О.М., Майоров А.Ю., Шестакова М.В. Классификация сахарного диабета. Всемирная организация здравоохранения 2019 г. Что нового? Сахарный диабет. 2020;23(4):329–39.

12. Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2022. Diab Care. 2022; 45:S17–38.

13. Дедов И.И., Шестакова М.В., Майоров А.Ю., ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 11. М., 2023. Доступно на: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf.

14. Stenström G., Gottsäter A., Bakhtadze E., et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54(Suppl. 2):S68–72. Doi: 10.2337/diabetes.54.suppl_2.s68.

15. Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol. 2019; 10:320. Doi: 10.3389/fphys.2019.00320.

16. Tuomi T., Groop L.C., Zimmet P.Z., et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993; 42:359–62. Doi: 10.2337/diab.42.2.359.

17. Zimmet P.Z., Tuomi T., Mackay I.R., et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diab Med. 1994; 11:299–303.

18. Cousminer D.L., Ahlqvist E., Mishra R., et al. Bone Mineral Density in Childhood Study. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diab Care. 2018; 41:2396–403.

19. Mishra R., Akerlund M., Cousminer D.L., et al. Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diab Care. 2020; 43:418–25.

20. Löfvenborg J.E., Andersson T., Carlsson P.O., et al. Fatty fish consumption and risk of latent autoimmune diabetes in adults. Nutr Diab. 2014;4(10): e139. Doi: 10.1038/nutd.2014.36.

21. de Candia P., Prattichizzo F., Garavelli S., et al. Type 2 Diabetes: How Much of an Autoimmune Disease? Front Endocrinol (Lausanne). 2019; 10:451. Doi: 10.3389/fendo.2019.00451.

22. Stenström G., Gottsäter A., Bakhtadze E., et al. Latent Autoimmune Diabetes in Adults: Definition, Prevalence, β-Cell Function, and Treatment. Diabetes. 2005;54(Suppl. 2):S68–72. Doi: 10.2337/diabetes.54.suppl_2.S68.

23. Xiang Y., Huang G., Zhu Y., et al. China National Diabetes and Metabolic Disorders Study Group. Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. Diab Obes Metab. 2019;21(4):893–902. Doi: 10.1111/dom.13595.

24. Mishra R., Hodge K.M., Cousminer D.L., et al. A Global Perspective of Latent Autoimmune Diabetes in Adults. Trends Endocrinol Metab. 2018;29(9):638–50. Doi: 10.1016/j.tem.2018.07.001.

25. Pilla S.J., Balasubramanyam A., Knowler W.C., et al. Look AHEAD Research Group. Islet autoantibody positivity in overweight and obese adults with type 2 diabetes. Autoimmunity. 2018 ;51:408–16.

26. Brooks-Worrell B., Hampe C.S., Hattery E.G., et al. GRADE β-cell Ancillary Study Network; GRADE Research Group. Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study. Diabetes. 2022; 71:1261–127.

27. Wada E., Onoue T., Kinoshita T., et al. Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study. Diabetologia. 2021;64(10):2183–92. Doi: 10.1007/s00125-021-05516-1.

28. Sørgjerd E.P. Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes. Curr Diab Rev. 2019;15(3):199–204. Doi: 10.2174/1573399814666180730105351.

29. Силко Ю.В., Никонова Т.В., Иванова О.Н. и др. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Тер. архив. 2016;88(10):42–5. Doi: https://doi.org/10.17116/terarkh2016881042-45.

30. Al-Majdoub M., Ali A., Storm P., et al. Metabolite profiling of LADA challenges the view of a metabolically distinct subtype. Diabetes. 2017; 66:806–14. Doi: 10.2337/db16-0779.

31. Zhou Z., Xu M., Xiong P., et al. Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM? Diab Metab Syndr. 2024;16(1):242. Doi: 10.1186/s13098-024-01479-6.

32. Siddiqui K., Nawaz S.S. Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy. Immunotargets Ther. 2023;12:91–103. Doi: 10.2147/ITT.S417917.

33. Sorgjerd E.P., Asvold B.O., Thorsby P.M., Grill V. Individuals fulfilling criteria for type 2 diabetes rather than LADA display transient signs of autoimmunity preceding diagnosis with possible clinical implications: the HUNT study. Diab Care. 2018; 41: e161–3. Doi: 10.2337/dc18-1069.

34. Buzzetti R., Zampetti S., Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13:674–86. Doi: 10.1038/nrendo.2017.99.

35. Maddaloni E., Coleman R.L., Agbaje O., et al. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet. Diab Endocrinol. 2020;8(3):206–15. Doi: 10.1016/S2213-8587(20)30003-6.